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Abstract
We undertook this study to understand how the transcription factor Sox2 contributes to the malignant phenotype of
glioblastoma multiforme (GBM), the most aggressive primary brain tumor. We initially looked for unbalanced genomic
rearrangements in the Sox2 locus in 42 GBM samples and found that Sox2 was amplified in 11.5% and overexpressed in all
the samples. These results prompted us to further investigate the mechanisms involved in Sox2 overexpression in GBM. We
analyzed the methylation status of the Sox2 promoter because high CpG density promoters are associated with key
developmental genes. The Sox2 promoter presented a CpG island that was hypomethylated in all the patient samples when
compared to normal cell lines. Treatment of Sox2-negative glioma cell lines with 5-azacitidine resulted in the re-expression
of Sox2 and in a change in the methylation status of the Sox2 promoter. We further confirmed these results by analyzing
data from GBM cases generated by The Cancer Genome Atlas project. We observed Sox2 overexpression (86%; N=414),
Sox2 gene amplification (8.5%; N=492), and Sox 2 promoter hypomethylation (100%; N=258), suggesting the relevance of
this factor in the malignant phenotype of GBMs. To further explore the role of Sox2, we performed in vitro analysis with
brain tumor stem cells (BTSCs) and established glioma cell lines. Downmodulation of Sox2 in BTSCs resulted in the loss of
their self-renewal properties. Surprisingly, ectopic expression of Sox2 in established glioma cells was not sufficient to
support self-renewal, suggesting that additional factors are required. Furthermore, we observed that ectopic Sox2
expression was sufficient to induce invasion and migration of glioma cells, and knockdown experiments demonstrated that
Sox2 was essential for maintaining these properties. Altogether, our data underscore the importance of a pleiotropic role of
Sox2 and suggest that it could be used as a therapeutic target in GBM.
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Introduction
Therapy for malignant gliomas is currently suboptimal. A better
understanding of the cellular and molecular features of these
tumors should propel the development of more effective therapies.
In 2004, two independent groups identified brain tumor stem cells
(BTSCs) as the tumor-initiating cells of glioblastoma multiforme
(GBM) [1,2]. This population of cells is thought to be responsible
for the invariable recurrence of GBM after treatment. BTSCs
possess traits similar to those of neural stem cells, such as the
property of self-renewal and the expression of several embryonic
stem cell markers. Moreover, a link has been reported between
aberrant expression levels of these embryonic stem cell markers
and the histological grade of gliomas [3,4]. Thus, abnormalities in
genes and pathways involved in the regulation of stem cell self-
renewal seem to be important in the stem cell model of cancer. In
agreement with this notion, Sox2, a critical transcription regulator
of embryonic and neural normal stem cell function [3,4], has been
reported to be dysregulated in several human cancers. Sox2 was
found to be frequently downregulated in gastric cancers [5] and
overexpressed in small-cell lung cancers, esophageal squamous
carcinomas, and basal cell-like breast carcinomas [3,6,7]. In
addition, the Sox2 locus was shown to be amplified in small-cell
lung cancer, esophageal squamous carcinomas [6,7], and, to a
lesser extent, in GBM [8].
Although overexpression of Sox2 mRNA has been reported in
malignant gliomas when compared with nonmalignant tissue [4],
an exhaustive molecular and mechanistic analysis of Sox2 has
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e26740never been performed. Therefore, the main purpose of this study
was to further investigate the status of Sox2 in GBM at the
molecular level and to elucidate how this transcription factor
contributes to the malignant phenotype of this lethal disease.
Results and Discussion
First, we investigated Sox2 expression in two independent
cohorts of 30 and 10 human surgical GBM specimens,
respectively. We found that Sox2 was overexpressed at the protein
level in all the analyzed tumors in the first cohort (30/30), and
screening revealed mRNA overexpression in 90% of the
specimens in the second cohort (9/10) (Figure 1A and 1B).
Interestingly, Sox2-positive cells were frequently observed in the
invasive tumoral front, but endothelial and inflammatory cells did
not stain positive for Sox2 (Figure 1A; and Figure S1A; and data
not shown). Since overexpression could be due to unbalanced
genomic rearrangements in the Sox2 locus, we analyzed the
genetic information of these tumors to determine Sox2 amplifi-
cation and found that Sox2 was amplified in 3/30 (10% incidence)
and 3/10 (30% incidence) of these samples (Figure 1C and 1D).
Next, we analyzed Sox2 expression in BTSCs and established
glioma cell lines. Sox2 mRNA expression was significantly higher
in BTSCs than in the established glioma cell lines (Figure S1B),
and Sox2 protein was more frequently detected in BTSCs (6/7)
than in established glioma cell lines (4/8) (Figure S1C). Sox2
amplification was present in both BTSCs (2/7) and established
glioma cell lines (1/7) (Figure S1D). These results prompted us to
further investigate the mechanisms involved in Sox2 overexpres-
sion in GBM. We first analyzed the methylation status of the Sox2
promoter because high-CpG-density promoters are associated
with key developmental genes [9]. Our data revealed that the Sox2
Figure 1. Molecular analysis of Sox2 in GBM specimens. A. Sox2 was overexpressed at the protein level in GBM samples. Representative
micrographs of Sox2 immunostaining in GBM samples (n=30). a, normal white matter with slight cytoplasmic staining in the cytoplasm; b, GBM with
intense nuclear staining in tumor cells and no vascular staining; c, Sox2-positive infiltrating cells in normal tissue around the tumor (206);
d, infiltrative border with Sox2-positive tumor cells (46). B. Sox2 was overexpressed at the mRNA level in GBM samples. This panel illustrates the
relative Sox2 mRNA expression levels in 10 GBM samples. The red dashed line represents the normal threshold. N=normal brain. C and D.
Amplification of Sox2 in the two independent cohorts (left, 30 GBM samples; right, 10 GBM samples). N=normal human astrocytes; A=leukemia cell
line TF1 (amplified Sox2). The red dashed lines represent the normal threshold.
doi:10.1371/journal.pone.0026740.g001
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tion start site (Figure 2A) that included part of the coding region
(Figure S2A). Analysis using methylation-specific polymerase chain
reaction ([PCR] MSP) of 12 GBM samples showed that the Sox2
promoter was hypomethylated in all 12 samples when compared
to normal human astrocytes (Figure 2B and S2B). Assessment of
Sox2 promoter methylation status in BTSCs and established
glioma cell lines confirmed that the Sox2 promoter was
hypomethylated in Sox2-expressing cell lines. In contrast, Sox2-
negative cell lines exhibited a methylated promoter pattern (Figure
S1B and S2B). Interestingly, this hypomethylated pattern in the
Sox2 promoter mirrors the one found in neural precursor cells
[10,11,12], suggesting that GBMs and BTSCs display a more
undifferentiated phenotype. To rule out other possible epigenetic
regulatory mechanisms, we treated two Sox2-negative cell lines
(U-87 MG and T98G) with the histone deacetylase inhibitor
trichostatin A (TSA) or with the DNA methyl-transferase inhibitor
5-azacitidine (AZA). Treatment with AZA, but not TSA, resulted
in the re-expression of Sox2 at the mRNA and protein levels
(Figure 2C and 2D), further supporting a pivotal role of aberrant
DNA promoter demethylation in the regulation of Sox2 levels in
GBM.
We validated these results by analyzing data from The Cancer
Genome Atlas (TCGA; [13], available at https://cgwb.nci.nih.
gov/cgi-bin/heatmap#TCGAGBM). In the sets of GBM speci-
mens from TCGA, we found Sox2 mRNA overexpression in
86.2% of the samples (357/414) (Figure 3A), amplification of the
Sox2 locus (3q26.33) copy number in 8.5% of the samples (42/
492) (Figure 3B), and hypomethylation of the promoter in 100% of
the samples when compared with normal controls (N=258)
(Figure 3C), again suggesting the relevance of this transcription
factor in the malignant phenotype of GBMs. Together, our results
indicate that Sox2 overexpression in GBM is regulated at the
genetic and epigenetic levels and that DNA promoter demethyl-
ation is the leading cause of Sox2 deregulation.
Next, to understand the functional role of Sox2 in GBM, we
knocked down Sox2 expression in NSC23 BTSCs by using two
independent small interfering RNAs (siRNAs). Downmodulation
of Sox2 jeopardized the neurosphere-forming activity, as indicated
by the results of both clonal neurosphere (Figure 4A) and limited
dilution assays (Figure S3A), and drove the cells to display a
differentiation expression profile (Figure 4B), thus indicating
impairment of the self-renewal phenotype of BTSCs. Moreover,
suppression of Sox2 prompted a decrease in cell viability
(Figure 4C), a decrease in bromodeoxyuridine (BrdU) incorpora-
tion (Figure 4D), accumulation of cells in the G0/G1 cell cycle
phase (Figure S3B), and a decrease in proliferation markers such as
E2F1 (Figure S3C). These phenotypic modifications were
evidenced by the generation of smaller neurospheres from Sox2-
knockdown cells than from parental BTSCs (Figure 4E). These
data indicate Sox2 is involved in the maintenance of a more
undifferentiated phenotype that includes the capacity of self-
renewal. We further confirmed these data in another BTSC line,
NSC11 (Figure S4A–S4D). Strikingly, when we introduced Sox2
in the Sox2-negative established cell line U-87 MG, we did not
observe the acquisition of self-renewal or neurosphere-forming
properties (Figure S5A–S5D), although we detected a modest but
significant increase in cell viability and proliferation (Figure S5E
and S5F). Similarly, established glioma cultures with endogenous
Sox2 overexpression did not display neurosphere formation when
cultured in enriched growth factor medium (Figure 5G). Collec-
tively, our data indicate that Sox2 is essential but not sufficient to
sustain self-renewal and that other factors cooperate to activate
stem cell-like properties in glioma cells.
Because infiltration and invasion are the main characteristics of
the malignant phenotype of gliomas, we sought to ascertain
whether Sox2 plays a role in the invasion/migration potential of
malignant gliomas. Downregulation of Sox2 using siRNA resulted
in a significant decrease in the migratory (Figure 5A) and invasive
capabilities (Figure 5B) of not only BTSCs (Figure S6A) but also
established glioma cells that express Sox2 (Figure S6A) This
phenomenon was associated with a significant decrease in the
expression of several proteins involved in migration, invasion, and
angiogenesis (Figure S6B). Interestingly, restoration of Sox2
expression in a Sox2-negative glioma cell line, U-87 MG, resulted
in a significant increase in the percentage of migratory and
invasive cells (Figure 5C, 5D and S6C).
Here, we present the first comprehensive report, to our
knowledge, of Sox2 overexpression mechanisms in GBM and
reveal a previously undescribed role of this transcription factor in
the invasion and migration properties of glioma BTSCs and cell
lines. We identified Sox2 promoter DNA hypomethylation as the
leading mechanism responsible for Sox2 aberrant expression in
GBM. The fact that the percentage of Sox2 amplification in
GBMs (13%) did not justify the high frequency of Sox2
overexpression in these tumors prompted us to search for other
molecular mechanisms, such as epigenetic dysregulation of the
Sox2 promoter or its regulators. In this regard, DNA hypomethy-
lation and histone acetylation are two of the mechanisms direct the
pluripotency/differentiation fate of neural stem cells [11,14]. Our
data revealed that Sox2 presents a high CpG density throughout
the promoter. These data are in accordance with other studies that
found that the Sox2 locus is flanked by two bivalent CpG islands
that, under certain physiological conditions, may poise the gene
for repression upon differentiation [12]. In this regard, our results
suggest that the Sox2 promoter hypomethylation we observed in
GBM reflects a more primitive cellular state resembling that found
in neural stem cells [12]. Even though our findings suggest that
DNA promoter hypomethylation is the major contributing factor
to Sox2 overexpression, others have shown that DNA methylation
patterns can be better explained by histone methylation patterns
than by CpG density [12,15]. Interestingly, in embryonic and
neural stem cells, the Sox2 promoter is enriched with the
transcription initiation mark H3k4me3, and this mark resolves to
H3k27me3 (which is known to be repressive) in differentiated cells
[12,16]. Therefore, we could not rule out that in GBM, the Sox2
promoter presents an enrichment of the positive transcription
mark H3k4me3; further experiments are needed to test this
hypothesis.
According to data from the present study and others [17], Sox2
overexpression in BTSCs is essential for maintaining the self-
renewal of BTSCs, as assessed by neurosphere-forming activity
and expression levels of pluripotent markers. Importantly, data
from our study suggest the involvement of critical factors besides
Sox2 in maintaining self-renewal. This function mimics a well-
described role of Sox2 in the developing central neural system, in
which Sox2 plays a critical role in maintaining the self-renewal
and pluripotency of the neural stem cells [18] in a coordinated
fashion with other transcriptional factors, such as Oct4 and Klf4 or
c-Myc [19,20].
Sox2 has been shown to maintain neural stem cell identity in the
developing brain. Constitutive expression of Sox2 inhibited
neuronal differentiation and preserved neural progenitor charac-
teristics, whereas inhibitionof Sox2 led to an early onset of neuronal
differentiation [21,22]. In the adult brain, Sox2 expression is
retained in the neural stem cell compartment [23]. Interestingly,
reduced expression of Sox2 in adult mice resulted in a substan-
tial reduction in proliferating neural precursors, suggesting an
Sox2 in Gliomas
PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e26740Figure 2. Methylation analysis of the Sox2 promoter gene. A. Analysis of the Sox2 promoter CpG content. The position of the Sox2 promoter
CpG island is shown. The vertical tic marks denote the CpGs in the island, and the position of the DNA methylation assay with MSP primers is shown.
B. MSP analysis of the promoter CpG islands of Sox2 in 12 patients with GBM. PCR products recognizing unmethylated (U) and methylated (M) CpG
sites were analyzed on 2% agarose gels. C+=positive control; in vitro methylated control, C2=negative control; DNA from normal brain and
ddH2O=water control containing no DNA. C. Relative expression of SOX2 mRNA following treatment with either vehicle (Veh), Trichostatin A (TSA),
or 5-aza-29-deoxycytidine (AZA;). Data were averaged from three independent experiments. Normal human astrocytes (NHAs) and U251 MG cell line
were used as negative and positive controls, respectively. D. Analysis of the expression of Sox2 protein following the same treatment described in C.
Data were averaged from three independent experiments. The U251 MG cell line was used as positive control.
doi:10.1371/journal.pone.0026740.g002
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proliferation in the adult brain [23,24]. In addition, our data show
that Sox2-driven malignant glioma cells are highly invasive and
have migratory characteristics mimicking those of neural stem cells
[25]. This finding supports those of other studies which showed that
Sox2 is expressed in the rostral migratory stream [23] and in the
migratory cells of the developing pituitary gland [26].
In our model, Sox2 was sufficient and essential for maintaining
the invasive properties of glioma cell lines and BTSCs. However,
further analysis is needed to address the in vivo role of Sox2 in the
migration and invasion in GBM. On the basis of our data, we
propose that Sox2 acts as an oncogene in GBM and that its
reactivation in glioma cells, due to its genomic amplification and
promoter hypomethylation, could be responsible for the acquisi-
tion of the invasive phenotype. Elucidation of the different Sox2-
related pathways that separate normal stem cells from BTSCs
should guide us in designing new and safe therapies for patients
with GBM.
Figure 3. TCGA Data Meta-analysis. A. Relative expression of Sox2 mRNA in 414 GBM samples from TCGA. Sox2 was overexpressed in 86% of the
samples (357/414). The red dashed lines represent the normal threshold. B. Amplification of the Sox2 locus in 492 GBM specimens from TCGA. Sox2
showed amplification in the number of copies (copy number $2.5 copies) in 8.5% of the samples (42/492). The red dashed lines represent the normal
copy number. C. Sox2 methylation status of 262 samples (258 tumors and 4 normal cell lines). These data show that Sox2 is methylated in the normal
cell lines and hypomethylated in 100% of the tumor samples.
doi:10.1371/journal.pone.0026740.g003
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PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e26740Figure 4. Role of Sox2 in self-renewal properties of GBM. A. Role of Sox2 in the self-renewal capabilities of BTSCs. Upper panel, quantification
of neurosphere formation percentage in Sox2-silenced NSC23 BTSC line. NSC23 cells were transfected with mock, vehicle (Veh), siRNA scramble
(siScrbl), or two different siRNAs against Sox2, Sox2 (I) and Sox2 (II), and the number of secondary spheres generated was assessed after 8–10 days. To
confirm that the spheroids were, indeed, formed by stem cells, we randomly selected at least 15 individual secondary spheres and subjected them to
further, long-term (2 months) propagation in each subcloning experiment. Lower panel, representative western blot of Sox2-silenced NSC23 cell line.
B. Assessment of differentiation/stem cell markers in Sox2-silenced BTSCs. The expression values of the markers were expressed as the log2 ratio of
the Sox2-silenced sample (siSox2) versus the siScramble-transfected sample (siScrbl). Data shown are from one representative experiment. C. Cell
viability analysis in Sox2-silenced BTSCs. Cell viability was examined 7 days later by MTT assay. D. Cell proliferation analysis in Sox2-silenced BTSCs.
Cell proliferation was evaluated by measuring the BrdU incorporation and expressed as a percentage of the mock-treated cells. E. Neurosphere size
evaluation in Sox2-silenced BTSCs. Upper panel, Quantification of the diameter of NSC23 neurosphere transfected with siScrbl or two different siRNAs
against Sox2, Sox2(I) and Sox2(II). Lower panel, representative micrographs of neurosphere size are depicted (50 mm magnification).
doi:10.1371/journal.pone.0026740.g004
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PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e26740Figure 5. Role of Sox2 in the migration and invasion properties of GBM. A. Assessment of cell migration of Sox2-silenced BTSCs. Sox2
regulates positively the migration ability of BTSCs. For transwell migration assays, NSC23 cells were untreated or transfected with siRNA scramble,
siRNA Sox2(I), or siRNA Sox2(II). Quantification of the migration is expressed as the number of migrating cells per high-power field (HPF; 640).
Bottom, representative micrographs of the transwell migration assay (106magnification). B. Assessment of cell invasion in Sox2-silenced BTSCs by
transwell invasion. Sox2 regulates positively the invasion ability of BTSCs. For transwell invasion assays, NSC23 cells were left untreated or transfected
with siRNA scramble, siRNA Sox2(I), or siRNA Sox2(II). Quantification of the invasion is expressed as the number of invasive cells per HPF. Bottom,
representative micrographs of the transwell invasion assay (106magnification). C. Assessment of migration in Sox2-overexpressing glioma cell lines
by wound assay. U-87 MG cells were left untreated or infected with 100 multiplicities of infection (MOIs) of an adenovirus vector containing an empty
cassette CMV (AdCMV), an adenovirus carrying LacZ cDNA (AdLacZ), or an adenovirus carrying Sox2 cDNA (AdSox2). Twenty-four hours later, 1610
5
cells were seeded in six-well plates and left until they reached 80% confluency. At that time (0 h), we performed a scratch with a pippette tip, and
repopulation of the wound was observed by light microscopy. D. Assessment of invasion in Sox2-overexpressing glioma cell lines by transwell
invasion. U-87 MG cells were left untreated or infected with 100 MOIs of an AdCMV, an AdLacZ, or an AdSox2. Invasion using Matrigel-coated
transwell was performed as in B. Quantification of the invasion is expressed as the number of invasive cells per HPF. Bottom, representative
micrographs of the transwell invasion assay (106magnification).
doi:10.1371/journal.pone.0026740.g005
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Cell Lines and Culture Conditions
The glioma cell lines LN229, U87 MG, U251 MG, U373,
A172, SNB19, D54, and T98G and the cell line NTERA2 were
obtained from the American Type Culture Collection. Cell lines
were maintained in Dulbecco’s modified Eagle’s medium/nutrient
mixture F12 (1:1, vol/vol) supplemented with 10% fetal bovine
serum in a humidified atmosphere containing 5% CO2 at 37uC.
Normal human astrocytes (NHAs) were purchased from Clo-
netics/BioWhittaker (Walkersville, MD) and were maintained in
astrocyte growth medium (AGM; in an AGM BulletKit) obtained
from Clonetics/BioWhittaker. Neurosphere cultures were estab-
lished from acute cell dissociation of human GBM surgical
specimens [1,27] and maintained in Dulbecco’s modified Eagle’s
medium/nutrient mixture F12 supplemented with B27 (Invitro-
gen, Carlsbad, CA), epidermal growth factor, and basic fibroblast
growth factor (20 ng/mL each; Sigma-Aldrich, St Louis, MO).
Sox2 Expression Levels by Quantitative PCR
The expression levels of Sox2 transcripts were quantified
relative to the expression level of the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by real-
time PCR (RT-PCR) using an ABI 7700 sequence detection
system (Applied Biosystems, Foster City, CA). The expression
levels relative to GAPDH were calculated using the ddCt method
and normalized with normal brain RNA (N) [28]. Primer
sequences are included in Text S1.
Assessment of SOX2 Amplification
To assess Sox2 amplification, we used the comparative ddCt
method with SYBR-green (LightCycler 480 SYBR Green I
Master; Roche, Manheim, Germany) for quantitative PCR (Q-
PCR). Primers were designed with PrimerExpress software
(Applied Biosystems), and we validated whether the efficiency of
the amplification of the chosen primer sets was equal to that of the
normalizer. A primer set for the EOMES and SLITRK3 genes
was used for normalization. We used the acute leukemia cell line
TF1 as a positive control for amplification (A) and NHAs as a
negative control (NHA). The validation experiments were
performed on fourfold serial dilutions of genomic DNA, starting
with 100 ng in the first dilution. For relative quantification, the
reaction mixtures consisted of LightCycler 480 SYBR Green I
Master (Roche) with 500 nM of each primer and 10 ng DNA in a
total volume of 25 ml. After an initial denaturation step for 10 min
at 95uC, thermal cycling conditions were 15 s at 95uC and 1 min
at 60uC for 40 cycles. Finally, the dissociation curves for each
reaction were determined. All samples were run in duplicate or
triplicate on an ABI 7700 sequence detection system (Applied
Biosystems). Primer sequences are included in Text S1.
Primer Design MSP Analysis
Primer sequences for MSP analysis were designed using
MSPPrimer [29], and their location in the SOX2 promoter is
indicated in Figure 2A. All primer sequences are included in Text
S1.
Assessment of SOX2 Promoter Methylation
For MSP analysis, DNA was extracted from cell lines and
patients using the DNeasy Kit (Quiagen; Valencia, CA). Bisulfite
modification of genomic DNA was carried out using the EZ DNA
methylation kit (Zymo Research; Irvine, CA). We analyzed SOX2
promoter methylation using MSP primer pairs covering the
putative transcriptional start site in the 59CpG island with 1 mLo f
bisulfite-treated DNA as a template and JumpStart Red Taq DNA
polymerase (Sigma) for amplification, as previously described [30].
Demethylation Studies
For demethylation studies, cultured cells were treated with
1 mmol/L 5-aza-29-deoxycytidine (Sigma) for 72 h, with the
medium changed every 24 h. Trichostatin A (Sigma) was used
to treat cells at a concentration of 300 nmol/L for 18 h. Vehicle
drug treatments were performed in parallel with drug-free media.
TCGA Data Meta-analysis
Results of copy number and gene expression status were
downloaded from the TCGA data portal. All the copy number
data from samples hybridized by Memorial-Sloan Kettering
Cancer Center using the Agilent Human Genome CGF micro-
array 244A (HG-CGH-244A) were downloaded. This dataset
included 492 matched pairs of tumor and normal samples. The
pipeline of TCGA directly provided the estimated copy number
for each of the probes in the array (summarization level 2,
according to TCGA). In particular, SOX2 was interrogated by
three different probes. The provided copy number is the average
of the copy numbers predicted by each probe. SOX2 was
amplified in the predicted copy numbers (copy number $2.5
copies) in 8.5% of the samples (42/492).
To determine gene expression, the analyzed selected samples
were hybridized by The Broad Institute using an Affymetrix HG-
U133A array (Affymetrix; Santa Clara, CA). It included 414
tumor samples plus 11 normal samples (not matched with the
previous ones). Two probe sets (213721_at and 213722_at) hit the
SOX2 gene. The average ‘‘normal’’ expression of the SOX2 gene
for each probe set was computed by taking the mean of the
logarithms of the signals of the probesets for normal samples. Once
this reference was obtained, the logarithm of the fold change for
each of the samples was computed by substracting this reference
value from the log of the signal of each of the probes. The
displayed fold change was the average fold change for both probe
sets. Concordance between both probe sets was very strong
(Pearson correlation coefficient=0.87, p%1e-16). SOX2 was
overexpressed at least twofold in 86% of the samples (357/414).
Finally, the selected data that were used to estimate the
methylation status were hybridized by the Johns Hopkins
University group using the Illumina GoldenGate Methylation
Cancer Panel I. It included the methylation status of 262 samples
(258 tumors and normal cell line in quadruplicate; B lymphocyte
cat# GM06990, Coriell Institute for Medical Research, Camden,
NJ). These data show that SOX2 was methylated in the normal
cell lines and hypomethylated in 100% of the tumor samples.
Self-renewal Analysis
Cells derived from the dissociation of clonal single neurospheres
were seeded in 96-well plates, and the number of generated
secondary spheres was assessed after 8–10 days. To avoid
including the colonies that may have been formed by transient
amplification of cells in these cultures, we counted only secondary
spheres that exceeded 120 mm in diameter. To confirm that the
latter were, indeed, formed by stem cells, we randomly selected at
least 15 individual secondary spheres and subjected them to
further, long-term (2 months) propagation in each subcloning
experiment.
Immunoblotting Assays
For the immunoblotting assays, cells were lysed in (3-[(3-
cholamidopropyl)-dimethylammonio]-1-propane sulfonate) buffer
Sox2 in Gliomas
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protein (20 mg) were resolved by the NuPAGE 4% to 20% Tris-
glycine gradient gel (Invitrogen), transferred to polyvinylidene
membranes, and blocked in 5% nonfat milk in phosphate-buffered
saline/Tween-20. Membranes were incubated with the following
antibodies: Sox2 (Cell Signaling, Danvers, MA) and a-Tubulin
(Sigma-Aldrich). The membranes were developed according to the
protocol for enhanced chemiluminiscence from Amersham
(Piscataway, NJ).
Neurosphere Size Analysis
To assess neurosphere size, cells derived from the dissociation of
clonal single neurospheres were seeded in 96-well plates, and the
size of the generated secondary spheres was assessed after 10 days.
We counted 20 neurospheres per sample, and the median
neurosphere size of each sample was plotted with 95% confidence
intervals. Images were captured and measured using a deconvolu-
tion microscope (Zeiss, Germany).
In Vitro Migration and Invasion Assays
For transwell migration assays, 1610
4 cells were plated in the
top chamber with the non-coated membrane (24-well insert; pore
size, 8 mm; BD Biosciences). For invasion assays, 1610
5 cells were
plated in the top chamber with a Matrigel-coated membrane (24-
well insert; pore size, 8 mm; BD Biosciences). In both assays, cells
were plated in medium without serum or growth factors, and
medium supplemented with 2% serum was used as a chemoat-
tractant in the lower chamber. The cells were then incubated for
24 h. Cells that did not migrate or invade through the pores were
removed by a cotton swab. Cells on the lower surface of the
membrane were stained with crystal violet and counted.
Statistical Analysis
For the in vitro experiments, statistical analyses were performed
using a two-tailed Student’s t test. Data are expressed as mean 6
standard deviation.
Supporting Information
Figure S1 Molecular analysis of Sox2 in GBM speci-
mens and cell lines. A. Summary of the Sox2 staining for the
30 GBM samples presented in Fig. 1A. Each score represents the
indicated range of positive percentage of intense nuclear Sox2-
positive cells. Tumors were distributed according to this score
analyzed independently in the central areas of the tumor or in the
normal/tumoral interface. B. Expression of Sox2 mRNA in
established glioma cell lines (n=10) and BTSC lines (n=12). RNA
was extracted and Q-RT-PCR was performed using Sox2
expression in normal human astrocytes (NHAs; Clonetics/
BioWhittaker, Walkersville, MD, USA) to normalize the data.
C. Expression of Sox2 in BTSC lines (n=7) and established
glioma cell lines (n=8). Normal human astrocytes (NHA) were
used as a negative control and the NTERA-2 (NTs) cell line was
used as a positive control. D. Amplification of Sox2 in 7 BTSCs
and 7 established glioma cell lines. N (Normal)=normal human
astrocytes; A (Amplifly)=leukemia cell line TF1, which is known
to have an amplification of SOX2 gene. We used the comparative
ddCt method with SYBR for Q-PCR. A primer set for the
EOMES and SLITRK3 genes was used for normalization. Red
dashed lines represent the normal threshold.
(TIF)
Figure S2 Analysis of the Sox2 promoter methylation
profile in BTSCs and established cell lines. A. Analysis of
the Sox2 gene CpG content. The positions of the CpG islands are
shown. The vertical tic marks depicts the CpG’s in the island. B.
MSP analysis of the promoter CpG islands of Sox2 in 10 BTSCs
lines, 9 established glioma cell lines and normal human astrocytes
(NHA). PCR products recognizing unmethylated (U) and
methylated (M) CpG sites are analyzed on 2% agarose gels.
C+=positive control; in-vitro methylated control, C2=negative
control; DNA from normal brain and ddH2O=water control
containing no DNA.
(TIF)
Figure S3 Role of Sox2 in self-renewal properties of
GBM. A. Quantification of Sox2 self-renewal capabilities of
BTSCs. using a limiting dilution assay as described previously (2,
21). After primary sphere formation was noted, NSC23 cultures
were dissociated and plated in 96-well microwell plates and cells
were transfected with mock, vehicle (Veh), siRNA scramble
(siScrbl) or two different siRNAs against Sox2, Sox2 (I) and Sox2
(II).. Final cell dilutions ranged from 200 cells/well to 1 cell/well.
Cultures were fed every 2 days until day 7, when the percentage of
wells not containing spheres for each cell plating density was
calculated and plotted against the number of cells/well. Regres-
sion lines were plotted, and x-intercept values were calculated;
these represent the number of cells required to form at least one
tumor sphere in every well. B. Evaluation of cell cycle in Sox2-
silenced BTSCs. Cells were transfected as indicated and 48 h later
fixed in cold 70% ethanol (in PBS) for 20 min. Then, cells were
stained with a mixture of propidium iodide (40 mg/ml) and
ribonuclease A (10 mg/ml) in PBS and incubated for 30 min at
37uC and subjected to flow cytometry analysis. The data represent
the means and 95% CIs of three different experiments. C.
Expression of different proliferation markers by Q-RT-PCR in
Sox2-silenced BTSCs. Sox2 was silenced as described above, and
48 h later RNA was Q-PCR analysis was performed. Quantifica-
tion of the expression of the indicated genes was performed using
TaqMan gene expression assays (Applied Biosystems) specific for
each gene. GAPDH was used as an internal control. To determine
relative gene expression, we used the comparative threshold cycle
method.
(TIF)
Figure S4 Role of Sox2 in the maintenance of self-
renewal properties of the BTSC line NSC11. A. Silencing
of Sox2 in NSC11 BTSCs. Cells were transfected with two
different siRNAs against Sox2 and subjected to Western blotting
48 h later. U-87 MG and the NTs cells were used as negative and
positive controls, respectively. B. Role of Sox2 in the self-renewal
capabilities of NSC11cells. NSC11 cells derived from the
dissociation of clonal single neurospheres were seeded in 96-well
plates, and the number of generated secondary spheres was
assessed after 8–10 days. To avoid including the colonies that may
have been formed by transient amplification of cells in these
cultures, we counted only secondary spheres that exceeded
120 mm in diameter. To confirm that the latter were, indeed,
formed by stem cells, we randomly selected at least 15 individual
secondary spheres and subjected them to further, long-term (2
months) propagation in each subcloning experiment. C. Role of
Sox2 in proliferation of NSC11 cells Cell proliferation was
evaluated using the BrdU cell proliferation enzyme-linked
immunosorbent assay from Calbiochem (EMD Chemicals)
according to the manufacturer’s recommendations. D. Impact of
Sox2 on NSC11 sphere size. Sox2 was silenced as described above
and cells derived from the dissociation of clonal single neuro-
spheres were seeded in 96-well plates, and the size of generated
secondary spheres was assessed after 10 days. Images were
Sox2 in Gliomas
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We counted 20 neurospheres per sample and means with 95% CIs
were plotted.
(TIF)
Figure S5 Evaluation of the role of Sox2 on the
established glioma cell lines. A. Overexpression of Sox2 in
Sox2-negative glioma cell lines. U-87 MG cells were left untreated
(mock) or infected (100 MOIs) with AdLacZ or AdSox2. Sox2
expression levels were evaluated at 24, 48, and 72 h using Western
blotting. The NTs cell line was used as a positive control. B.
Assessment of self-renewal in U-87 MG cells expressing exogenous
Sox2. U-87 MG cells were left untreated (mock) or infected (at 100
MOIs) with an empty adenoviral vector (AdCMV), or AdLacZ or
AdSox2. The U-87 MG cell line was cultured using the conditions
described above for neurosphere cultures and allowed to grow for
48 h. Cells were then seeded in 96-well plates, and the number of
generated secondary spheres was assessed after 8–10 days. C and
D. Cell size evaluation in the Sox2-overexpressing U-87 MG cell
line. U-87 MG cells were cultured in neurosphere medium and
allow to form neurospheres. Cells derived from the dissociation of
clonal single neurospheres were seeded in 96-well plates, and the
size of the generated secondary spheres was assessed after 10 days.
Images were captured and measured using a deconvolution
microscope (Zeiss). We counted 20 neurospheres per sample and
the means with 95% CIs were plotted. E. Cell viability analysis in
the Sox2-overexpressing U-87 MG cell line. U-87 MG cells were
seeded then treated with the indicated treatments. Twenty-four
hours later, cells were tripsinized and seeded at 2000 cells/well in
96-well plates and allowed to grow for 7 days. MTT experiments
were performed to quantify cell viability. F. Cell proliferation
analysis in the Sox2-overexpressing U-87 MG cell line. Cell
proliferation was evaluated using the BrdU cell proliferation
enzyme-linked immunosorbent assay from Calbiochem (EMD
Chemicals, Gibbstown, NJ) according to the manufacturer’s
recommendations. U-87 MG cells were treated as above G.
Assessment of self-renewal in Sox2-positive glioma cell lines U373
and LN229. Both cell lines were allowed to grow in either 10%
serum or conditions to culture neurospheres. Cells were then
seeded in 96-well plates, and the number of generated spheres was
assessed after 10 days. Results of clones growing as attached
cultures were quantified (please note that no neuropsheres were
observed). Data are expressed as the means with 95% CIs from
three independent experiments.
(TIF)
Figure S6 Role of Sox2 in the invasive phenotype of
gliomas. A. Assessment of invasion in Sox2-silenced BTSCs
(NSC11, NSC7-26) and Sox2-positive glioma (LN229) cell lines.
For transwell invasion assays NSC11, NSC6-27, or LN229 cells
were left untreated or transfected with a scramble siRNA (50 nM),
Sox2 (I), or Sox2(II) (50 nM; Ambion). Twenty-four h later, 1610
5
cells were plated in the top chamber with a Matrigel-coated
membrane (24-well insert; pore size, 8 mm; BD Biosciences). Cells
were plated in medium without serum or growth factors, and
medium supplemented with 2% serum was used as a chemoat-
tractant in the lower chamber. The cells were then incubated for
24 h. Cells that did not invade through the pores were removed
using a cotton swab. Cells on the lower surface of the membrane
were stained with crystal violet and counted. Quantification of the
invasion is expressed as the number of invasive cells per field.
Bottom, representative micrographs of the transwell invasion assay
(106 magnification). B. Analysis of invasion markers in Sox2-
silenced NSC11, NSC7-26 and LN229 cells. Sox2 was silenced as
described above. Quantification of the expression of the indicated
genes was performed using TaqMan gene expression assays
(Applied Biosystems) specific for each gene. GAPDH was used as an
internal control. For normalization, the cDNA equivalent to input
RNA was measured in duplicate for GAPDH transcripts by RT-
PCR. To determine relative gene expression, we used the
comparative threshold cycle method. C. Assessment of migration
in Sox2-overexpressing glioma cell lines by transwell migration. U-
87 MG cells were left untreated or infected with 100 MOIs of
AdCMV, AdLacZ cDNA, or AdSox2. Twenty-four h later, 1610
4
cells were plated in the top chamber with a noncoated membrane
(24-well insert; pore size, 8 mm; BD Biosciences). Cells were plated
in medium without serum or growth factors, and medium
supplemented with 2% serum was used as a chemoattractant in
the lower chamber. The cells were then incubated for 24 h. Cells
that did not invade through the pores were removed using a cotton
swab. Cells on the lower surface of the membrane were stained
with crystal violet and counted. Top, quantification of the invasion
expressed as the number of migrating cells per HPF. Bottom,
representative micrographs of the transwell migration assay (106
magnification).
(TIF)
Text S1 Primer sequences.
(DOC)
Acknowledgments
The authors thank Markeda Wade, Dawn Chalaire, and Stephanie
Deming (Department of Scientific Publications, The University of Texas
MD Anderson Cancer Center) for editorial assistance and Joy Gumin
(Department of Neurosurgery, The University of Texas MD Anderson
Cancer Center) for the generation of the brain tumor stem cultures.
Author Contributions
Conceived and designed the experiments: MMA JF RD-V LM CG-M
MAI AR. Performed the experiments: MMA RD-V LM AR DL NC-S CV
LU PJ. Analyzed the data: MMA RD-V LM AR AA CG-M JF MAI.
Contributed reagents/materials/analysis tools: ALdM NS AR AA ST-S
MDO EB JG-F FFL. Wrote the paper: MMA CG-M.
References
1. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, et al. (2004) Isolation and
characterization of tumorigenic, stem-like neural precursors from human
glioblastoma. Cancer Res 64: 7011–7021.
2. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004)
Identification of human brain tumour initiating cells.[see comment]. Nature
432: 396–401.
3. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An
embryonic stem cell-like gene expression signature in poorly differentiated
aggressive human tumors. Nat Genet 40: 499–507.
4. Schmitz M, Temme A, Senner V, Ebner R, Schwind S, et al. (2007)
Identification of SOX2 as a novel glioma-associated antigen and potential
target for T cell-based immunotherapy. Br J Cancer 96: 1293–1301.
5. Otsubo T, Akiyama Y, Yanagihara K, Yuasa Y (2008) SOX2 is frequently
downregulated in gastric cancers and inhibits cell growth through cell-cycle
arrest and apoptosis. Br J Cancer 98: 824–831.
6. Hussenet T, Dali S, Exinger J, Monga B, Jost B, et al. SOX2 is an oncogene
activated by recurrent 3q26.3 amplifications in human lung squamous cell
carcinomas. PLoS One 5: 8960.
7. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, et al. (2009) SOX2 is an
amplified lineage-survival oncogene in lung and esophageal squamous cell
carcinomas. Nat Genet 41: 1238–1242.
8. Annovazzi L, Mellai M, Caldera V, Valente G, Schiffer D () SOX2 Expression
and Amplification in Gliomas and Glioma Cell Lines. Cancer Genomics
Proteomics 8: 139–147.
Sox2 in Gliomas
PLoS ONE | www.plosone.org 10 November 2011 | Volume 6 | Issue 11 | e267409. Saxonov S, Berg P, Brutlag DL (2006) A genome-wide analysis of CpG
dinucleotides in the human genome distinguishes two distinct classes of
promoters. Proc Natl Acad Sci U S A 103: 1412–1417.
10. Shimozaki K, Namihira M, Nakashima K, Taga T (2005) Stage- and site-
specific DNA demethylation during neural cell development from embryonic
stem cells. J Neurochem 93: 432–439.
11. Blelloch R, Wang Z, Meissner A, Pollard S, Smith A, et al. (2006)
Reprogramming efficiency following somatic cell nuclear transfer is influenced
by the differentiation and methylation state of the donor nucleus. Stem Cells 24:
2007–2013.
12. Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, et al. (2007) Genome-
wide maps of chromatin state in pluripotent and lineage-committed cells. Nature
448: 553–560.
13. Cancer Genome Atlas Research Network (2008) Comprehensive genomic
characterization defines human glioblastoma genes and core pathways. Nature
455: 1061–1068.
14. Sikorska M, Sandhu JK, Deb-Rinker P, Jezierski A, Leblanc J, et al. (2008)
Epigenetic modifications of SOX2 enhancers, SRR1 and SRR2, correlate with
in vitro neural differentiation. J Neurosci Res 86: 1680–1693.
15. Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, et al. (2008) Genome-
scale DNA methylation maps of pluripotent and differentiated cells. Nature 454:
766–770.
16. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, et al. (2006) A
bivalent chromatin structure marks key developmental genes in embryonic stem
cells. Cell 125: 315–326.
17. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, et al. (2009)
SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation
and loss of tumorigenicity. Stem Cells 27: 40–48.
18. Suh H, Consiglio A, Ray J, Sawai T, D’Amour KA, et al. (2007) In vivo fate
analysis reveals the multipotent and self-renewal capacities of Sox2+ neural stem
cells in the adult hippocampus. Cell Stem Cell 1: 515–528.
19. Kim JB, Zaehres H, Wu G, Gentile L, Ko K, et al. (2008) Pluripotent stem cells
induced from adult neural stem cells by reprogramming with two factors. Nature
454: 646–650.
20. Masui S, Nakatake Y, Toyooka Y, Shimosato D, Yagi R, et al. (2007)
Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse
embryonic stem cells. Nat Cell Biol 9: 625–635.
21. Bylund M, Andersson E, Novitch BG, Muhr J (2003) Vertebrate neurogenesis is
counteracted by Sox1-3 activity. Nat Neurosci 6: 1162–1168.
22. Graham V, Khudyakov J, Ellis P, Pevny L (2003) SOX2 functions to maintain
neural progenitor identity. Neuron 39: 749–765.
23. Ferri AL, Cavallaro M, Braida D, Di Cristofano A, Canta A, et al. (2004) Sox2
deficiency causes neurodegeneration and impaired neurogenesis in the adult
mouse brain. Development 131: 3805–3819.
24. Episkopou V (2005) SOX2 functions in adult neural stem cells. Trends Neurosci
28: 219–221.
25. Cayre M, Canoll P, Goldman JE (2009) Cell migration in the normal and
pathological postnatal mammalian brain. Prog Neurobiol 88: 41–63.
26. Fauquier T, Rizzoti K, Dattani M, Lovell-Badge R, Robinson IC (2008) SOX2-
expressing progenitor cells generate all of the major cell types in the adult mouse
pituitary gland. Proc Natl Acad Sci U S A 105: 2907–2912.
27. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, et al. (2006) Tumor stem cells
derived from glioblastomas cultured in bFGF and EGF more closely mirror the
phenotype and genotype of primary tumors than do serum-cultured cell lines.
Cancer Cell 9: 391–403.
28. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using
real-time quantitative PCR and the 2(2Delta Delta C(T)) Method. Methods 25:
402–408.
29. Brandes JC, Carraway H, Herman JG (2007) Optimal primer design using the
novel primer design program: MSPprimer provides accurate methylation
analysis of the ATM promoter. Oncogene 26: 6229–6237.
30. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-
specific PCR: a novel PCR assay for methylation status of CpG islands. Proc
Natl Acad Sci U S A 93: 9821–9826.
Sox2 in Gliomas
PLoS ONE | www.plosone.org 11 November 2011 | Volume 6 | Issue 11 | e26740